APMA Asks MACs to Cease Adverse Actions on Amniotic Injections and Provide Clarification | News | APMA
APMA Asks MACs to Cease Adverse Actions on Amniotic Injections and Provide Clarification

APMA Asks MACs to Cease Adverse Actions on Amniotic Injections and Provide Clarification Members Only Content

On March 11, APMA sent a request to all Part B Medicare Administrative Contractors (MACs) about its concerns with their announcement in late February that Medicare does not cover manipulated amniotic and/or placental tissue biologics for injections to treat illness for claims with dates of services on or after December 6, 2019.

This content is available to APMA members only. If you are a member, please log in to see the full content.



Related Resources

APMA and AADA Comment on FCSO Surgical Nail Changes

Learn More

APMA Continues to Address CAC Engagement with MAC Workgroup

Learn More

ADVERTISEMENT
Read the lastest issue of APMA News from anywhere!